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Abstract
Background: ADAR enzymes convert adenosines to inosines within double-stranded RNAs, including microRNA
(miRNA) precursors, with important consequences on miRNA retargeting and expression. ADAR2 activity is impaired
in glioblastoma and its rescue has anti-tumoral effects. However, how ADAR2 activity may impact the miRNome
and the progression of glioblastoma is not known.
Results: By integrating deep-sequencing and array approaches with bioinformatics analyses and molecular studies,
we show that ADAR2 is essential to edit a small number of mature miRNAs and to significantly modulate the
expression of about 90 miRNAs in glioblastoma cells. Specifically, the rescue of ADAR2 activity in cancer cells recovers
the edited miRNA population lost in glioblastoma cell lines and tissues, and rebalances expression of onco-miRNAs and
tumor suppressor miRNAs to the levels observed in normal human brain. We report that the major effect of ADAR2 is
to reduce the expression of a large number of miRNAs, most of which act as onco-miRNAs. ADAR2 can edit miR-222/221
and miR-21 precursors and decrease the expression of the corresponding mature onco-miRNAs in vivo and in vitro, with
important effects on cell proliferation and migration.
Conclusions: Our findings disclose an additional layer of complexity in miRNome regulation and provide information
to better understand the impact of ADAR2 editing enzyme in glioblastoma. We propose that ADAR2 is a key factor for
maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer.
Background
MicroRNAs (miRNAs or miRs) are small non-coding
single-stranded RNAs that play a crucial role in many
cellular pathways by silencing RNA targets by either
inhibiting their translation or promoting their degrad-
ation [1]. miRNAs are transcribed in the nucleus and the
nascent transcripts are called primary miRNAs (pri-miR-
NAs). Pri-miRNAs can be several kilobases long and
contain one or more secondary stem-loop structures [2].
The nuclear pri-miRNA transcripts are cleaved by a nu-
clear RNAse III enzyme, Drosha [2], which acts in con-
cert with several co-factors, including DGCR8 [3], to
generate stem-loop precursor miRNAs (pre-miRNAs).
Pre-miRNAs undergo a second cleavage by the cytoplas-
mic RNAse III enzyme Dicer, which, in cooperation with
other cofactors, cuts the loop end of pre-miRNAs. The
resulting product is an approximately 22 nucleotide
RNA duplex composed of the mature miRNA guide and
a passenger strand (also referred to as miRNA*). Once
loaded into the RNA-induced silencing complex (RISC),
the mature miRNA strand is able to recognize the target
RNA through a six to eight nucleotide seed region at the
5′ end of the miRNA, while the passenger strand is usu-
ally degraded [4].
miRNAs are important regulatory RNAs involved in
numerous cellular processes, including proliferation, dif-
ferentiation and development. Since miRNAs can act as
oncogenes or tumor suppressors [5], fluctuations of their
expression are important factors in both normal and
pathological conditions, including cancer [1,5]. Recently,
miRNAs have been shown to be differentially expressed
in malignant astrocytomas and glioblastomas (also known
as astrocytoma grade IV) compared with normal brain,
with some miRNAs, such as miR-21, miR-221 and
miR-222, being particularly over-expressed in cancers [6,7].
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Adenosine (A) to inosine (I) RNA editing, which is
mediated by the ADARs, adenosine deaminase enzymes
acting on double-stranded RNAs (dsRNAs), is a wide-
spread post-transcriptional mechanism in mammals that
affects several coding and regulatory RNAs, including
miRNA precursors, by altering their sequence and struc-
ture. Indeed, inosines are recognized as guanosines (G)
by the splicing and translation machineries and dsRNAs
containing I∙U wobble base pairs can interfere with the
action of RNA-binding proteins such as Dicer [8].
Therefore, A-to-I RNA editing events, equivalent to A-
to-G cDNA changes, may induce amino acid substitu-
tions, alter RNA splicing sites and perturb dsRNA struc-
tures. In mammals, there are three ADAR enzymes:
ADAR1 and ADAR2 are active deaminases, whereas
ADAR3 seems to be an inactive enzyme [9]. All ADARs
have a similar domain structure with a catalytic domain
at the carboxyl terminus and two or three dsRNA-binding
domains at the amino terminus [9]. Recently, it has been
shown that ADARs can interact with the miRNA world in
both an editing-dependent and -independent way [10,11].
Specifically, ADARs can edit miRNA precursors and thus
alter their maturation steps [12]. Moreover, when editing
occurs within the miRNA seed, this can lead to redirection
of the edited miRNA to a different subset of mRNA tar-
gets [13]. It has also been shown that ADARs can impair
miRNA maturation independently of their catalytic do-
mains, with ADAR1 able to globally enhance miRNA
biogenesis by directly interacting with Dicer [14,15].
ADAR2 is an essential enzyme for brain development
and function [16,17]. In previous studies, we and others
showed that ADAR2 activity is impaired in glioblastoma
in both children and adults [18-20] and that the decrease
of ADAR2-mediated editing correlates with increased
tumor grade in children [18]. Moreover, we recently dem-
onstrated that ADAR2 deaminase activity is sufficient to
inhibit glioblastoma proliferation and tumor growth, as it
modulates the CDC14B/Skp2/p21/p27 pathway in adult
glioblastoma cell lines and this was further confirmed in
different grades of pediatric glioma [21].
Due to the importance of ADAR2 activity in glioblast-
oma and the link between ADARs and miRNAs, we de-
cided to analyze miRNA profiles in glioblastoma cells
upon ADAR2 over-expression or silencing as well as in
normal brain and glioblastoma tissues, with the aim of
identifying important ADAR2-regulated miRNAs in glio-
blastoma. We found that ADAR2 specifically edits a
small number of mature miRNAs. Moreover, it is able to
modulate the expression of many miRNAs, most of
which are involved in tumorigenesis. In particular, we
found that the maturation steps of the important onco-
genic miR-221, -222 and -21 are inhibited by ADAR2
editing activity, with consequent effects on the prolifera-
tive and migratory capacities of glioblastoma cells.
Results
ADAR2 editing activity alters the miRNA expression
profile in glioblastoma
A-to-I RNA editing within miRNA precursors can alter
their maturation steps and consequently the expression
levels of mature miRNAs [12]. To investigate the effects
mediated by ADAR2 editing activity on the miRNome
(microRNA expression and editing profile), we used both
microarray and deep-sequencing approaches, followed by an
extensive bioinformatic analysis, in human brain and glio-
blastoma tissues as well as in a glioblastoma cell line (U118)
in which we modulated ADAR2 expression and/or activity.
Microarray expression analysis was performed to com-
pare RNA isolated from glioblastoma U118 cells trans-
fected with either the active ADAR2 or the inactive
ADAR2 enzyme (ADAR2 E/A) [21]. ADAR2 E/A carries
a single point mutation (E/A) in the catalytic domain,
which renders it unable to promote the deamination re-
action but still able to bind dsRNAs [22]. Both the active
and inactive ADAR2 were expressed at similar levels in
the stably transfected U118 cell lines (Figure S1 in
Additional file 1). Three independent miRNA-array ex-
periments were performed using total RNA extracted
from U118 over-expressing either ADAR2 or ADAR2 E/A.
In these cells, exogenous ADAR2 is expressed at approxi-
mately three-fold the level of the endogenous protein
levels and this is sufficient to rescue the normal editing
levels at well-known editing sites [21]. We selected only
miRNAs exhibiting a log2(ratio) of at least ±0.5 (corre-
sponding to ≥1.41 relative fold-change) (Additional file 2,
ADAR2 versus ADAR2 E/A, E column). For the statistical
analysis we applied the standard Benjamini-Hochberg
multiple testing correction adopting a cutoff false discov-
ery rate (FDR) ≤0.2 (Additional file 2; see Materials and
methods). Over-expression of the active ADAR2 caused
significant changes in the expression of several miRNAs
(46 miRNAs), compared with the inactive ADAR2 E/A
(Additional file 2). Among the down-regulated miRNAs,
miR-29b, miR-221 and miR-21 were the most reduced in
ADAR2 cells (-1.82, -1.65 and -1.59 log-fold, respectively;
Additional file 2, column in green). Strikingly, 40 out of
46 of the ADAR2 target miRNAs are involved in cancer
development/progression (Additional file 2, column in light
brown). Specifically, approximately 80% (13/19) of the
down-regulated miRNAs and approximately 30% (8/27)
of the over-expressed miRNAs play a role in glioblast-
oma (Additional file 2, column in light gray). Of note,
approximately 52% (10/19) of miRNAs down-regulated
by ADAR2 are usually over-expressed and act as onco-
miRNAs in glioblastoma (Additional file 2, column in dark
gray). Moreover, approximately 20% (5/27) of miRNAs
up-regulated by ADAR2 have a role as tumor suppres-
sors and/or are usually down-regulated in glioblastoma
(Additional file 2, column in dark gray).
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No significant changes in miRNA expression were de-
tected between ADAR2 E/A transfected cells and the
control U118 cell line (Additional file 2, untransfected
versus ADAR2 E/A).
In summary, miRNA-array data showed that ADAR2
activity restricts the expression of several well-known
onco-miRNAs in glioblastoma (Additional file 2, ADAR2
versus ADAR2 E/A, column in dark gray), with mir-221,
miR-21, miR-125b and miR-222 being the most down-
regulated.
ADAR2 edits a few miRNAs and alters the expression of
many miRNAs
Current miRNA arrays have pre-designed probe se-
quences that do not give information about the possible
sequence modification events within miRNAs. Addition-
ally, any editing events within the mature sequence
could alter the binding between the probe and the miR-
NAs. Therefore, we also carried out a deep-sequencing
analysis of small RNA fractions isolated from the U118,
U118 ADAR2, U118 ADAR2 E/A and U118 siADAR2
cells (in which we silenced the over-expressed ADAR2
enzyme) [21]. Additionally, we further extended our ana-
lysis to healthy human brain and glioblastoma tissues.
Mature miRNAs from these samples were sequenced
using the Illumina HiSeq2000 platform. No significant
A-to-G changes were identified in the U118 untrans-
fected cells (Table 1), confirming the notion that ADAR2
is either inactive or has greatly reduced activity in high-
grade astrocytoma/glioblastoma cell lines [18,23]. Intro-
ducing the active ADAR2 into U118 cells, we identified
19 editing sites within 18 miRNAs (Table 1). Nine sites
were also found to be edited at statistically significant
levels in human brains whereas only two of these were
edited in glioblastoma tissue (Table 1). We are confident
that these miRNAs are specifically edited by ADAR2,
since (i) the inactive ADAR2 E/A cell line shows no sig-
nificant A-to-G changes and (ii) decreased editing values
were observed in the ADAR2-silenced cell line (siA-
DAR2 versus ADAR2 cells) (Table 1). Most of these edi-
ted miRNAs had already been identified in our previous
study [23]; however, here we detected new potential edit-
ing sites in miR-210, miR-503 and miR-3157* (shown in
italics in Table 1). The identified editing sites were char-
acterized by an enrichment of uridine (U) in the up-
stream nucleotide position, with guanosine (G) usually
as the downstream nucleotide and with the nucleotide
opposing the editing site usually being a cytidine (C) or
Table 1 ADAR2-mediated editing events in brain and glioblastoma cells and tissues










Chr9 + hsa-let-7d* 0.3 2.0 0 0.5 1.61E-10 1.2 0.7 0 66 5
Chr17 - hsa-mir-22 0 0.1 0 0.1 5.50E-34 0 0 0 67 15
Chr19 - hsa-mir-24–2* 0.1 16.4 0 7.1 <1E-155 0.8 2.3 ND 18 6
Chr19 - hsa-mir-27a* 0.1 22.5 0.1 9.8 <1E-155 ND 0 2.6 10 1
Chr21 + hsa-mir-99a 0.1 13.8 0 6.9 <1E-155 5.0 1.2 0 13 1
Chr11 - hsa-mir-100 0 0.2 0 0.1 1.22E-145 0 0 0 13 1
Chr3 + hsa-mir-138–1* 0 0.8 0 0.5 2.57E-35 2.1 0.2 ND 74 12
Chr8 - hsa-mir-151 0.1 0.3 0 0.2 5.70E-13 0.9 0.6 ND 49 3
Chr11 - hsa-mir-210 0 0.5 0 0.5 2.31E-11 ND ND 0 77 12
Chr14 + hsa-mir-411 0 12.6 0 5.6 4.31E-39 15.3 13.9 3.2 20 5
Chrx - hsa-mir-421 0.2 13.8 0.5 9.6 <1E-155 1.8 1.0 0 61 14
Chr9 + hsa-mir-455 0 14.2 0 5.7 <1E-155 1.2 0.9 0 32 17
Chr17 - hsa-mir-497 0 26.1 0 16.7 1.73E-155 6.2 0.6 0 25 2
Chrx - hsa-mir-503 0 5.9 0 1.7 8.75E-14 ND ND 0 7 2
Chr7 - hsa-mir-589* 2.3 9.5 2.2 2.9 1.36E-31 70.0 74.1 0 66 6
Chr19 - hsa-mir-641 0 17.0 0 8.8 5.83E-116 0 0 0 17 2
Chr19 - hsa-mir-641 0 3.0 0 0.9 2.45E-14 0 3.6 0 18 3
Chr10 - hsa-mir-3157* 0 69.4 0 54.5 1.55E-90 ND ND 0 70 13
Chr16 + hsa-mir-3176 0 10.9 0 8.2 6.73E-41 ND ND 0 74 15
A-to-G changes in mature miRNAs isolated from U118 cell lines (untreated, ADAR2, ADAR2 E/A, siADAR2), human brains (pooled and frontal lobe) and
glioblastoma. The statistically significant modifications are marked in bold; the edited miRNAs that were not identified in our previous analysis are indicated in
italics [23]; miRNAs that are both edited and modulated by ADAR2 are indicated in bold (Additional files 2 and 3).
Editing levels are represented as percentages. ND, not determined (with <10 reads).
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a uridine (U). These sequence patterns are consistent
with genuine A-to-I editing [24]. Of note, 9 out of 19 of
the editing sites identified in the ADAR2 transfected
cells (Table 1) are located within the miRNA seed region
(including the new miR-503). Importantly, editing within
the seed sequence may lead to miRNA retargeting [13].
Next, we extended our analysis to possible alterations
of miRNA expression mediated by ADAR2 in glioblast-
oma cells and in human brain tissues (both normal brain
and glioblastoma), detecting differences in expression
that cannot be explained by the expected Poisson noise
[25]. We first analyzed the modulation of miRNA ex-
pression in ADAR2 versus ADAR2 E/A U118 cells and
in siADAR2 versus ADAR2 U118 cells, focusing our atten-
tion on those miRNAs that were up- or down-regulated
by ADAR2 and which reversed their expression-trend in
the siADAR2 cells (Additional file 3). We selected mature
miRNAs with (i) normalized counts greater than 200 reads
(ADAR2 plus ADAR2 E/A reads) and (ii) a log2(ratio) be-
tween ADAR2 and ADAR2 E/A exceeding 0.5 (in absolute
value) (Additional file 3). A total of 91 miRNAs with sta-
tistically significant differences in expression were identi-
fied (Additional file 3), with 60 miRNAs down- and 31
up-regulated miRNAs in ADAR2 versus ADAR2 E/A cells
(Additional file 3), indicating that ADAR2 preferentially
restricts miRNA expression. This trend was also observed
when we concentrated on the most highly expressed miR-
NAs (ADAR2 plus ADAR2 E/A ≥10.000 reads): 13 out of
16 miRNAs were down-regulated and only 3 out of 16
miRNAs were up-regulated by ADAR2 (Table 2). Of note,
almost all the miRNAs significantly modulated by ADAR2
were also known to be involved in cancer development/
progression (Table 2).
miRNA expression was also analyzed in human healthy
brain and glioblastoma tissues, as glioblastoma tissues
have reduced ADAR2 activity [18-20]. We selected mature
miRNAs with (i) normalized counts greater than 200 reads
and (ii) a log2(ratio) between human brain and glioblast-
oma exceeding 0.5 (in absolute value) (Additional file 4).
We identified a total of 293 differently expressed miRNAs
between brain and glioblastoma (Additional file 4). Of
these miRNAs, 56 were among those significantly
expressed in U118 cells and modulated by ADAR2.
ADAR2 ‘corrected’ about 50% of the miRNAs (27/56)
that were deregulated in glioblastoma (shown in gray
in Additional file 4).
Comparing miRNA editing (Table 1) and expression
(Additional file 2 and Additional file 3), we observed that
relatively few miRNAs were both edited and significantly
modulated by ADAR2 (shown in bold in Table 1): miR-22,
miR-503 (Additional file 2), miR-138-1* and miR-455
(Additional file 3).
Overall, we identified four miRNAs that are both edited
and differentially expressed by ADAR2 (shown in bold in
Table 1), 14 miRNAs that are edited but not significantly
modulated by ADAR2 (Table 1) and 89 miRNAs that are
modulated (either up-regulated or down-regulated) by
ADAR2 but not edited within their mature sequence
(Additional file 3; excluding the edited miR-138-1* and
miR-455).
Table 2 miRNAs highly expressed in glioblastoma cells and modulated by ADAR2






Chr9 hsa-let-7d 0 18,813 13,703 −14.1995 13.7423 Yes
Chr2 hsa-miR-10b 0 11,101 559 −13.4385 9.1293 Yes
Chr7 hsa-miR-335* 5,296 14,463 5,463 −1.4492 0.0448 No
Chr5 hsa-miR-143 61,575 159,453 81,440 −1.3727 0.4034 Yes
Chr7 hsa-miR-25 29,424 58,238 35,063 −0.9849 0.2529 Yes
Chr19 hsa-let-7e 30,846 56,890 36,482 −0.8831 0.2421 Yes
Chr7 hsa-miR-29a 33,734 59,096 49,119 −0.8088 0.5421 Yes
Chr17 hsa-miR-21 919,239 1,506,954 1,384,694 −0.7131 0.1581 Yes
Chr17 hsa-miR-21* 53,970 84,276 106,392 −0.6430 0.9791 Yes
Chr3 hsa-miR-138-1* 4,460 6,714 5,063 −0.5900 0.1829 Yes
Chrx hsa-miR-222 277,271 410,972 348,219 −0.5677 0.3287 Yes
Chr19 hsa-miR-769 6,339 9,225 6,433 −0.5412 0.0212 No
Chr6 hsa-miR-30a* 9,650 13,716 13,235 −0.5072 0.4619 Yes
Chr10 hsa-miR-146b 12,692 6,639 10,948 0.9348 −0.2132 Yes
Chr2 hsa-miR-548 s 11,559 8 22 10.3269 −8.3083 No
Chr19 hsa-miR-520c 14,093 0 0 13.7828 −13.7828 Yes
Highly expressed mature miRNAs in U118 glioblastoma cells (ADAR2 plus ADAR2 E/A ≥10,000 reads).
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ADAR2 activity reduces the levels of the oncogenic
miR-221, -222 and -21 by blocking maturation of their
precursors
ADAR2 editing activity is progressively lost in astrocyto-
mas from low to high grade in children [18]. Interestingly,
we observed that the rescue of active ADAR2 in glioblast-
oma cells (U118) results in the down-regulation of a large
number of miRNAs (Additional file 3), including three im-
portant onco-miRNAs (miR-221, miR-222 and miR-21),
which play a pivotal role in cancer progression and are
found particularly over-expressed in glioblastoma [26,27].
In order to validate the deep-sequencing and micro-
array data and to explore the connection between
ADAR2 activity and miR-221, miR-222 and miR-21, we
used two glioblastoma cell lines (U118 and A172) stably
over-expressing either ADAR2 or its inactive form
ADAR2 E/A at similar levels (Figure S1 in Additional file 1
and data not shown). By using these cell lines, we con-
firmed that the active ADAR2 editing enzyme significantly
decreases the levels of mature miR-221, miR-222 and
miR-21 compared with the controls (untreated and
ADAR2 E/A cells), as tested by quantitative real-time
PCR (qRT-PCR) (Figure 1a, b) and northern blotting
analysis (Figure S2 in Additional file 1). As miRNA con-
trol, we analyzed the levels of miR-223 (Figure 1c), which
were found to be unchanged by ADAR2 as observed in
miRNA array and deep-sequencing experiments.
Conversely, silencing of ADAR2 in U118 ADAR2 cells
(Figure 2a) increased the expression levels of mature
miR-221, miR-222 and miR-21 (Figure 2b). Similar results
were also found in A172 silenced cells (data not shown).
It has been shown that ADARs can alter the structure
and the sequence of miRNA precursors, thus blocking
Drosha and Dicer activity, resulting in reduced mature
miRNAs and in concomitant accumulation of their pre-
cursors [11,28]. Therefore, we tested the precursor levels
of miR-221, miR-222 and miR-21 in the ADAR2-modified
cell lines. While the levels of mature miR-221, miR-222
and miR-21 decreased (Figure 1a, b), the corresponding
precursors (pri- or pre-miRNAs) accumulated in both
U118 and A172 cells upon ADAR2 expression (Figure 3).
Specifically, we observed that the endogenous pri-miR-
221 and pri-miR-222 levels increase in ADAR2 glioblast-
oma cells compared with both the inactive ADAR2 E/A
Figure 1 Down-regulation of selected onco-miRNAs (miR-221, miR-222 and miR-21) in glioblastoma cell lines upon ADAR2 expression.
(a) Mature miR-221, miR-222 and miR-21 expression levels are shown in untreated (ctrl, dark gray), ADAR2 over-expressed (ADAR2, medium gray)
and inactive ADAR2 over-expressed (ADAR2 E/A, light gray) U118 cell lines. Values represent the mean of at least three independent quantitative
RT-PCRs (qRT-PCRs). Error bars represent standard error of the mean (s.e.m.) (n = 3), **P < 0.01, *P < 0.05. (b) The same experiments shown in (a)
were performed in the A172 cell lines. (c) Mature miR-223 expression levels are shown in U118 (upper panel) and in A172 (lower panel) cell lines.
Mean ± s.e.m. (n = 2). All the samples were normalized to RNU6B levels. The expression levels were calculated as a relative-fold increase compared
with untreated cells (ctrl) arbitrarily set to 1.
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and the untreated cells (Figure 3a, b). In the case of miR-
21 it was the pre-miR-21 rather than the pri-miR-21 that
accumulated in the ADAR2 glioblastoma cells, as tested
by qRT-PCR (Figure 3c) and northern blotting analysis
(Figure S3 in Additional file 1).
Overall, these data demonstrate that ADAR2 deami-
nase activity results in accumulation of miR-222/221
and miR-21 precursors in two glioblastoma cell lines,
with a concomitant reduction of the corresponding
mature onco-miRNAs.
Adar2 inhibits miR-221, miR-222 and miR-21 expression
in vivo
In order to verify our observation in vivo, we took advan-
tage of RNA samples extracted from Adar2-/- and wild-
type mouse brains. If Adar2 is important for the matur-
ation of miR-221, miR-222 and miR-21 in physiological
conditions, we would expect a substantial increase in ex-
pression of these three miRNAs in the absence of Adar2.
We examined the endogenous levels of miR-221, miR-222
and miR-21 and of their precursors by qRT-PCR and
found that their mature miRNA are indeed significantly
over-expressed in the Adar2-/- mouse brain (+2.7-, +2.2-
and +2.7-fold, respectively) compared with the wild type
(Figure 4a). We also observed an approximately 40% de-
crease in the level of their precursors (pri-miRs) in the
absence of Adar2 (Figure 4b).
Our results indicate that the ADAR2 enzyme controls
miRNA expression, not only in cancer cells, but also in
normal mammalian brain.
ADAR2 edits the pri-miR-221, -222 and -21 precursors
In order to validate our findings in a different cell sys-
tem, we used HEK293T cells, which show very low
ADAR2 editing activity [18]. The cells were transfected
with the pri-miR-222/221 cluster or pri-miR-21, either
alone or together with the ADAR2 or ADAR2 E/A plas-
mids (Figure S4 in Additional file 1). Transcripts from
these pri-miRNA plasmids had previously been shown
to be efficiently processed by mammalian cell machiner-
ies in different cell lines [26,29]. We also confirmed
these results in HEK293T cells (data not shown). The
final amount of mature miRNAs and the corresponding
precursors were analyzed 48 h post-transfection by qRT-
Figure 2 ADAR2 silencing in U118 cell line increases miR-221, miR-222 and miR-21 expression levels. (a) Left: qRT-PCRs of ADAR2 in U118
ADAR2 (ctrl, dark gray) and the same cell line stably transfected with siADAR2 (siADAR2, medium gray) or scramble (scr, light gray) plasmids. Each
sample was normalized to GAPDH mRNA levels. Mean ± standard error of the mean (s.e.m.) (n = 3), **P < 0.01. Right: a representative immunoblot
of ADAR2 in the cell lines analyzed. (b) Mature miR-221 (left panel), miR-222 (middle panel) and miR-21 (right panel) expression levels in U118
ADAR2, siADAR2 and scramble cell lines are shown. Each sample was normalized to RNU6B levels. Mean ± s.e.m. (n = 3), **P < 0.01, *P < 0.05. The
expression levels were calculated as a relative-fold increase compared with U118 ADAR2 (ctrl) arbitrarily set to 1.
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PCR. As observed in glioblastoma cells and in mouse
brain, we found that ADAR2 (but not its inactive ver-
sion) reduces the levels of mature miR-221, miR-222
and miR-21 (endogenous plus transfected) compared
with controls in HEK293T cells (Figure 5a), with the
concomitant accumulation of their respective miRNA
precursors (Figure 5b). Of note, in this cell system and
similarly to mouse brain (Figure 4b), ADAR2 can accu-
mulate pri-miR-21 (Figure 5b), whereas only the pre-
miR-21 was affected by ADAR2 activity in glioblastoma
cells (Figure 3).
Since the inactive ADAR2 E/A did not alter the ex-
pression of these onco-miRNAs (Figures 1, 3 and 5), we
hypothesized that possible editing events may occur
within pri-miR-221, -222 and -21. To test this possibility,
we took advantage of a cell system in which ADAR2 ac-
tivity was strongly enhanced (HEK293T transiently
transfected with ADAR2; Figure S4 in Additional file 1).
RT-PCRs were designed to amplify over-expressed pri-
miR-222/221, pri-miR-21 and pri-miR-223 (the latter
was used as control) from ADAR2 or ADAR2 E/A
HEK293T cells. PCR products were analyzed using three
different methods: (i) direct sequencing of cDNA pools,
(ii) single-clone sequencing reactions (with 40 to 100 in-
dependent clones/sample) and (iii) MiSeq technology
(Illumina). Editing events were detected as A-to-G
changes in the cDNA sequences. According to the single
clone analyses, approximately 20% of each pri-miRNA
molecules carry A-to-G changes. Specifically, we found
that 28% of the pri-miR-221 clones, 18% of the pri-miR-
222 clones and 25% of the pri-miR-21 clones had A-to-G
changes.
Overall, the pri-miR-221 was edited at 12 sites, with
the most edited sites being positions -1, +1, +34, +64
and +187 (with editing levels ranging from 4% to 8%;
Figure 6a). Pri-miR-222 was found edited at nine sites:
Figure 3 Modulation of miR-221, miR-222 and miR-21 precursors in glioblastoma cell lines upon ADAR2 and ADAR2 E/A expression.
(a) Pri-miR-221, pri-miR-222 and pri-miR-21 expression levels analyzed by qRT-PCR in U118 untreated (ctrl, dark gray), U118 over-expressing ADAR2
(ADAR2, medium gray) and U118 over-expressing ADAR2 E/A (ADAR2 E/A, light gray) cell lines. Each sample was normalized to GAPDH mRNA
levels. Mean ± standard error of the mean (s.e.m.) (n = 3), **P < 0.01. (b) The same set of experiments in (a) was performed in the A172 cell line.
(c) Pre-miR-21 expression levels in U118 (upper panel) and A172 (bottom panel) cell lines were analyzed by qRT-PCR. For the pre-miRs assay each
sample was normalized to RNU6B levels. Mean ± s.e.m. (n = 3), **P < 0.01, *P < 0.05. The expression levels were calculated as a relative-fold increase
compared with untreated cells (ctrl) arbitrarily set to 1.
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the most edited positions were -4 and +53, which were
20% and 9% edited, respectively (Figure 6b). Pri-miR-21
was edited at eight different positions (all located within
the pre-miR sequence), with positions +16, +46 and +51
being edited between 9% and 15% (Figure 6c). The A-to-
G substitutions we observed are due to ADAR2 activity,
and not to RT/sequencing errors/artifacts, as no substi-
tutions were observed in the control ADAR2 E/A cell
line (single clone analysis and MiSeq; Figure 6). As a fur-
ther control, we co-transfected the pri-miR-223 and the
ADAR2 plasmids in HEK293T cells in order to test
whether ADAR2 can edit any dsRNA structure of
miRNA precursors in our over-expressing conditions.
No A-to-G changes were found within pri-miR-223
sequences (as tested by single-clone analysis with ap-
proximately 70 screened clones, data not shown). Fluctua-
tions in editing percentages detected by different methods
are mainly due to their different accuracy/sensitivity, as
the sequences analyzed ranged from just a few (cDNA
pool), to dozens (single clones), to thousands (MiSeq).
We also investigated editing events in these three pri-
miRNAs (pri-miR-222/221 and -21) in vivo, using total
RNA isolated from human brain tissue (single individual
or commercial RNA pools) with similar sequencing
technologies. Among the A-to-G changes identified in
the over-expressing HEK293T system, some were also
found in the human adult and pediatric brain samples.
Specifically, A-to-G changes were found within pri-miR-
221 (sites -15, +39 and +41), pri-miR-222 (sites -21 and
+70) and pri-miR-21 (sites +12 and +41) (Figure 6, adeno-
sines marked with red circles). All these positions showed
extremely low percentages of A-to-G changes, ranging
from 1.5 to 3% in the different RNA brain samples, with
the only exception being site -21 within pri-miR-222,
which was highly edited in different human samples: ap-
proximately 20% in adult brain (Clontech), approximately
15% in the adult brain pool (Ambion) and approximately
4% in pediatric brain.
None of the A-to-G changes identified in this study
have been reported as single nucleotide polymor-
phisms [30,31].
Edited miRNA precursors can undergo rapid degrad-
ation due to the action of specific inosine-dependent
ribonucleases, such as Tudor-SN [12,32], and the 2′-
deoxythimidine 3′,5′-bisphosphate (pdTp) can inhibit
Tudor-SN activity [12]. In order to see if Tudor-SN
could degrade our substrates, we examined the pri-
miR-221, -222 and -21 sequences (cDNA pools) from
Figure 4 Altered expression of mature and primary miR-221, -222 and -21 in wild-type and Adar2-/- mouse brain tissue. (a) Mature
miR-221 (left panel), miR-222 (middle panel) and miR-21 (right panel) expression levels were analyzed using specific qRT-PCRs in wild-type
(WT, dark gray) and Adar2-/- (medium gray) mouse brain tissue. (b) Primary miR-221 (left panel), pri-miR-222 (middle panel) and pri-miR-21
(right panel) expression levels were measured using specific qRT-PCRs in the same samples. Mature miRNAs were normalized to RNU6B and
pri-miRNAs were normalized to β-actin levels. The expression levels were calculated as a relative-fold increase compared with the wild-type
samples arbitrarily set to 1. Mean ± standard error of the mean (n = 3), **P < 0.01, *P < 0.05.
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ADAR2 HEK293T cells treated with the pdTp inhibitor
as previously described [12]. We did not observe any
increase in RNA editing levels compared with the con-
trol cells in these conditions (data not shown).
Overall, our data demonstrate that ADAR2 is able to
edit the pri-miR-222/221 and the pri-miR-21 transcripts
both in vivo and in cell lines. In order to verify whether
the editing events detected in these three pri-miRs might
have an effect on their maturation, we substituted gua-
nosines (by site-specific mutagenesis) within these pri-
miR-plasmids at the sites with the highest editing levels
as detected by MiSeq analysis (for pri-miR-221: -1, +1,
+64; for pri-miR-222: -21, -4, +53; for pri-miR-21: +16,
+46, +51) (adenosines marked with circles in Figure 7).
The mutagenized and wild-type plasmids were then
transfected into HeLa cells. We switched to the HeLa
cells as they have an extremely low endogenous level of
the mature miR-221, -222 and -21. This thus enabled us
to quantify exogenous miRNA expression changes reli-
ably without background noise. We transfected HeLa
cells with the wild-type or the edited versions (at single
or multiple sites) of each pri-miRNA plasmid and we
monitored the expression levels of mature miRNAs as
well as miRNAs*. We observed a significant reduction
of miR-221 and -222 levels when we used the edited
pri-miRNAs versus the unedited ones (Figure 7a, b).
Specifically, A-to-G mutagenesis at all the three pri-
miR-221 editing sites (-1, +1, +64) strongly inhibited
miRNA maturation, with the -1 and +1 sites strongly
influencing the maturation process, whereas the +64
site was involved to a lesser extent (Figure 7a). Simi-
larly, the A-to-G mutations of the pri-miR-222 at the
-21 and +53 sites play a major role in inhibiting miR-
222 maturation, while that at the -4 site does not
(Figure 7b). To further confirm that the reduction in
mature miR-221 and -222 levels detected after trans-
fection of the edited pri-miRNA plasmids was due to
alterations in their processing, we also analyzed the
levels of miR-221* and miR-222*, finding similar re-
sults (Figure 7a, b).
Surprisingly, no effect was observed when the edited
pri-miR-21 plasmid was used (Figure 7c), demonstrating
that mutagenesis at these three selected edited sites did
not affect miR-21 processing.
Figure 5 Modulation of miR-221, miR-222 and miR-21 and their precursors in HEK293T cell lines upon ADAR2 and ADAR2 E/A expression.
(a) Expression levels, using qRT-PCR, of mature miR-221 (left panel), miR-222 (middle panel) and miR-21 (right panel) in HEK293T cells transiently
co-transfected with either pri-miR-222/221 or pri-miR-21 plasmids and with ADAR2 or ADAR2 E/A. (b) In the same cells, the pri-miR-221
(left panel), pri-miR-222 (middle panel) and pri-miR-21 (right panel) expression levels measured by qRT-PCR are shown. Mature miRNAs and
pri-miRNAs were normalized using RNU6B and GAPDH, respectively. The expression levels were calculated as a relative-fold increase compared
with the sample transfected with the pri-miR-222/221 or pri-miR-21 plasmid arbitrarily set to 1. Mean ± standard error of the mean (n = 3),
**P < 0.01, *P < 0.05.
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ADAR2 decreases proliferation and migration of
glioblastoma cells by inhibiting miR-221, miR-222 and
miR-21 maturation
We have previously shown that editing activity mediated
by ADAR2 in glioblastoma cells decreases cell prolifera-
tion and migration both in vitro and in vivo, while glio-
blastoma cells transfected with the inactive ADAR2 E/A
enzyme retain malignant features similar to the un-
treated cells [18,21]. In order to test whether the de-
crease in miR-221, -222 and -21 levels mediated by
ADAR2 reduces cell aggressivity, we over-expressed
miR-221, -222 or -21 in ADAR2 glioblastoma cells and
evaluated their effects on cell proliferation and migra-
tion, generally affected by these three miRNAs. We tran-
siently transfected an equal amount (100 nM) of scramble
or miR-221- plus miR-222-mimic in U118 ADAR2 cells
(Figures S5a in Additional file 1). We monitored cell pro-
liferation of the untransfected and transfected U118
cells over four days, observing that while the presence
of ADAR2 alone inhibited cell proliferation compared
with the untreated cells, the combination of the two
miRNAs considerably increased cell proliferation (at 48 to
72 h post-transfection; Figure 8a). Next, we assessed
the protein expression levels of a well-known target of
miR-221 and -222, p27Kip1 [33]. This protein is down-
expressed in glioblastomas and plays a pivotal role at
the G1/S cell cycle checkpoint [34]. As expected, the
level of p27Kip1 decreased upon miRNA-mimic transfection
compared with U118 ADAR2 scramble or U118 ADAR2
cells (Figure 8b). Similar results were also observed in
another glioblastoma cell line (A172) (Figures S5c and
S6a,b in Additional file 1).
Of note, the U118 ADAR2 E/A cells (which have a
high level of both miR-221 and miR-222 and a high pro-
liferative rate) did not show cell proliferation increases
comparable to that observed in the ADAR2 cells when
Figure 6 ADAR2-mediated editing events within pri-miR-221, pri-miR-222 and pri-miR-21 in HEK293T cells. (a-c) Left: editing sites and
percentages of the pri-miR-221 (a), pri-miR-222 (b) and pri-miR-21 (c) are shown. Right: stem-loop structures of each precursor with the edited
sites indicated by red and gray circles (the site +187 of pri-miR-221 is not shown in the structure). Adenosines found edited in both ADAR2
HEK293T cells and human brain samples are indicated by red circles. Of note, the site -21 within pri-miR-222 was found highly edited in different
human samples, with values increasing from children (4%) to adult (approximately 20%) brain.
Tomaselli et al. Genome Biology  (2015) 16:5 Page 10 of 19
they were transfected with miR-221- plus miR-222-mimic
(Figures S7 in Additional file 1). This effect is probably
due to the high levels of these miRNAs in highly malignant
glioblastoma cells [35] that are thus not ‘corrected/
decreased’ by the ADAR2 activity. These data indicate
that the reduction of miR-221 and -222 levels medi-
ated by ADAR2 editing activity contributes signifi-
cantly to the inhibition of glioblastoma proliferation.
miR-21 is involved in cell proliferation and cell migra-
tion [36]. Among the validated miR-21 target genes,
PDCD4 plays an important role in cancer cell migration
[37]. In our previous study, we showed that ADAR2 in-
hibits glioblastoma cell migration [18]. Here, we demon-
strate that the expression of ADAR2 in glioblastoma
cells can significantly down-modulate miR-21 and up-
regulate PDCD4 protein levels in the U118 (Figure 8c)
and A172 (Figures S6c in Additional file 1) cell lines. To
evaluate whether miR-21 transfection can abolish the
inhibition of cell migration caused by ADAR2, we over-
expressed either miR-21-mimic or scramble (100 nM) in
U118 and A172 ADAR2 cells (Figures S5b, d in Additional
file 1). We monitored cell migration by wound healing
Figure 7 miRNA maturation of the wild-type and the edited versions of pri-miR-221, pri-miR-222 and pri-miR-21. (a) Left: the pri-miR-221
sequence structure, indicating the mutagenized/edited positions. Right: the mature miR-221 and -221* levels were measured by qRT-PCR in
untreated HeLa cells (untr, black) and in HeLa cells transfected with wild-type pri-miR-221 (221 WT, dark gray), fully edited pri-miR-221 (221 ED,
light gray) or pri-miR-221 edited at specific sites (221 ED +64; 221 ED -1,+1). (b) Left: the pri-miR-222 sequence structure, indicating the mutagenized/edited
positions. Right: the mature miR-222 and -222* levels were measured by qRT-PCR in untreated HeLa cells (untr, black) and in HeLa cells transfected with
wild-type pri-miR-222 (222 WT, dark gray), fully edited pri-miR-222 (222 ED, light gray) or pri-miR-222 edited at specific sites (222 ED +53; 222 ED -4; 222
ED -21; 222 ED -4,-21). (c) Left: the pri-miR-21 sequence structure, indicating the mutagenized/edited positions. Right: the mature miR-21 levels were
measured by qRT-PCR in untreated HeLa cells (untr, black) and in HeLa cells transfected with wild-type pri-miR-21 (21 WT, dark gray) or edited
pri-miR-21 (at sites +16, +46, +51) (21 ED, light gray). Mature miRNAs were normalized using RNU6B. The expression levels were calculated as a
relative-fold increase compared with the untreated cells and arbitrarily set to 1. Mean ± standard error of the mean (n = 3), **P < 0.01, *P < 0.05
when each sample is compared with the corresponding wild-type pri-miR.
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assay over 24 h, a time interval in which the cells do not
divide (data not shown). We observed that cell migration
increases in both U118 (Figure 8d) and A172 (Figures S6
in Additional file 1d) cell lines upon miR-21 over-
expression. Altogether, these data indicate that ADAR2
exerts its anti-proliferative and anti-migratory activity in
glioblastoma also through the modulation of miR-221,
miR-222 and miR-21.
Discussion
It is becoming clear that a large number of RNA-
binding proteins join forces to create an additional layer
of complexity in miRNA maturation and function. It is
thus critical that we gain a better understanding of the
mechanisms by which they control miRNAs and affect
normal physiology and disease [38].
Herein, we show that ADAR2, an essential RNA-
binding protein that converts A-to-I in dsRNAs, plays a
critical role in controlling miRNA expression levels and
determining their final sequence. By analyzing normal
brain and glioblastoma tissues as well as ADAR2-
modified glioblastoma cells, we found that: 1) selected
miRNAs undergo ADAR2-mediated editing in normal
brain, some of which is within the seed sequence; 2)
editing within miRNAs is decreased (or lost) in glioblast-
oma, where ADAR2 activity is impaired, compared with
normal brain; 3) glioblastomas have altered miRNA
expression profiles when compared with normal brain;
4) the rescue of ADAR2 activity in glioblastoma cells
restores the edited miRNA population and tends to re-
balance the miRNA expression profile (onco-miRNAs
versus tumor suppressor miRNAs) towards a state re-
sembling normal brain tissue; 5) the most striking effect
of ADAR2 rescue in glioblastoma cells is a general de-
crease in the levels of several onco-miRNAs (such as
miR-221, -222, -21); 6) ADAR2 can edit miR-222/221
and miR-21 precursors and decrease the expression of
the corresponding mature miRNAs both in vivo (mouse
brain) and in human glioblastoma cells, and this has sig-
nificant effects on cell proliferation and migration.
In our previous study, we demonstrated that ADAR2
activity is progressively lost during the progression of as-
trocytoma malignancy grade in children (from grade I to
grade IV) and that this contributes to cancer progression
Figure 8 The ADAR2-mediated anti-tumoral effect is reversed by miR-221, miR-222 and miR-21 expression. (a) U118 cells (8 × 104;
untreated, dark gray), U118 ADAR2 cells (ADAR2, medium gray), and U118 ADAR2 cells transiently transfected with either scramble mimic
(ADAR2 + scr, light gray) or with a mix of miR-221- and miR-222-mimic (ADAR2 +miR-221/222, red) were seeded and proliferation was monitored over
3 days. U118 untransfected cells (untreated, dark gray) were used as control. Error bars indicate standard deviations of four independent experiments.
Mean ± standard deviation (n = 4), **P < 0.01 when ADAR2 plus miR-221/222 cells (red) are compared with the ADAR2 (dark gray) and ADAR2 plus
scramble (light gray). (b) Protein lysates were extracted from the cells shown in (a) and analyzed by immunoblotting for p27Kip1, a target of miR-221
and miR-222. (c) PDCD4 protein analysis after immunoblotting of total protein extracts from U118 ADAR2 and ADAR2 E/A cell lines and the corresponding
quantitative densitometric analysis are shown. Each sample was normalized to GAPDH and compared with the ADAR2 E/A cells arbitrarily set to 1. A
representative sample of two independent experiments is shown. (d) Representative photographs of U118 ADAR2 cells transfected with scramble
mimic (scr) and miR-21-mimic (miR-21) at 0, 15 and 21 h after scratching the surface of monolayers cells. Only the U118 ADAR2 plus miR-21 cells show
an increase in motility when compared with the control cells (scr). The wound healing assay was performed in a time interval in which the cells do
not divide (data not shown).
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[18]. Here, we show that ADAR2 activity is fundamental
for miRNA homeostasis and we identify ADAR2 as an
important factor for miRNA expression and function in
both normal and cancer cells.
The most important information that comes from
ADAR2 rescue in glioblastoma cells is that this enzyme
can modulate the expression of a large number of miR-
NAs. The general tendency observed is that ADAR2
limits the expression of many miRNAs and most espe-
cially of onco-miRs. This finding is intriguing, as ADAR2
may thus have the opposite effect to the other RNA edit-
ing enzyme, ADAR1, which has recently been shown to
enhance miRNA processing [14].
Among the onco-miRNAs down-expressed by ADAR2,
we focused on miR-221, miR-222 and miR-21. These
miRNAs are often over-expressed in tumors, including
glioblastoma [6]. We show that ADAR2 activity inhibits
miR-221, -222 and -21 maturation and causes accumula-
tion of their precursors in different cell lines (including
glioblastoma cells) and in normal mouse brain. Consist
with this, we found a significant increase of miR-221,
-222 and -21 levels in Adar2-/- mouse brain, with a con-
comitant decrease of the corresponding precursors. Edit-
ing of miRNA precursors may impair the production of
mature miRNAs [11]. Considering that the inactive
ADAR2 E/A did not alter miRNA expression (miR-221,
-222 and -21), we tested whether editing events may
occur within their pri-miRNAs. Using an over-
expressing cell system (HEK293T), we identified mul-
tiple editing sites (with editing levels ranging from 2% to
20%) within the stem-loop structure of pri-miR-222/221
and pri-miR-21, but not within the control pri-miR-223.
The integrity of the dsRNA stem structure of miRNA
precursors is essential for their maturation [2]. Most of
the identified A-to-I editing events replace an A-U or U-
A Watson-Crick pair with a less stable I∙U or U∙I wobble
pair, leading to changes in the stem structure and/or sta-
bility. Investigating the miRNA maturation process of
wild-type and the edited versions of pri-miR-222/221,
we found that editing at the chosen positions did indeed
affect miRNA processing, since both miRNA and miRNA*
expression levels were impaired. Conversely, the mutagen-
ized/edited pri-miR-21 (carrying three A-to-G changes)
was processed normally, indicating that the selected sites
were not involved in miR-21 maturation, at least in our
system. Previous studies reported that not all the editing
events in pri-miRNA affect Drosha cleavage [12]. Indeed,
we show that only specific editing events (or combinations of
events) within miRNA precursors affect miRNA maturation.
We have to underline that ADAR2 can edit multiple
substrates in vivo; therefore, we cannot exclude the pos-
sibility that ADAR2 may control miRNA expression not
only by editing miRNA precursors directly but also by
editing other RNAs involved in miRNA maturation.
Some of the editing sites within pri-miR-222/221 and
pri-miR-21 identified in the ADAR2 HEK293T cells were
also detected in normal human brain, even if at low per-
centages compared with the cell system. Only site -21
within pri-miR-222 was found to be highly edited in dif-
ferent human brain samples, with editing increasing
from child (4%) to adult (approximately 20%) brain.
Interestingly, this editing position alone (which is located
in the lower stem of pri-miR-222 in the extension of the
pre-miRNA structure [39] and distant from the Drosha
cleavage site) is able to hamper miR-222 maturation by
more than 50% (Figure 7b). Also of note, miR-222 de-
creases its expression during porcine brain development
from embryonic to adult cortex [40]. Overall, our find-
ings indicate a connection between ADAR2-mediated
editing of miR-222 and brain development.
The generally low editing frequencies observed within
the three precursors in this study in vivo could be due to
the action of inosine-dependent nucleases, such as Tudor-
SN, that can degrade edited miRNA precursors [12,32].
However, the inhibition of Tudor-SN by pdTp did not in-
crease editing levels in our cell system (HEK293T), in con-
trast to previous reports on other miRNA precursors in
HEK293T cells [12]. However, a recent study demon-
strated the existence of a novel inosine-dependent nucle-
ase [41]; therefore, we cannot exclude the possibility that
different inosine-dependent nucleases may play a role in
the fate of specific edited miRNA precursors in vivo, such
as the ones identified in this study.
We previously showed that ADAR2 rescue in glioblast-
oma cells has important anti-tumoral effects, such as the
inhibition of cell proliferation and migration [18,21]. It is
conceivable that ADAR2 also exerts its anti-tumoral ef-
fects through miRNA modulation, such as of miR-221,
miR-222 and miR-21. In order to explore this possibility,
we reintroduced miR-221 and miR-222 into ADAR2-
modified glioblastoma cells (U118 and A172) and ana-
lyzed cell proliferation. The over-expression of miR-221
plus miR-222 caused a significant boost in cell prolifera-
tion and abolished the anti-tumoral effect of ADAR2.
These data indicate that miR-221 and miR-222 are im-
portant mediators of the effects of ADAR2, through
which this enzyme plays its anti-proliferative role in glio-
blastoma cells. In our previous study, we identified the
CDC14B transcript as an essential ADAR2 target gene,
acting over the Skp2/p21/p27 pathway, whose editing
slows down cell proliferation [21]. Here, we found that
two miRNAs (miR-221 and miR-222) that act in the
same molecular pathway (through p27Kip1) are also
modulated by ADAR2 activity, indicating that this path-
way is particularly sensitive to epigenetic mechanisms
such as RNA editing (Figure 9).
We also previously showed that ADAR2 plays an im-
portant role in inhibiting glioblastoma cell migration
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[18]. Here, we demonstrate that ADAR2 strongly down-
modulates miR-21 and up-regulates PDCD4 protein
(PDCD4 is a validated miR-21 target gene [37]) and that
this has important consequences in inhibiting glioblastoma
cell migration (Figure 8c,d and S6c,d in Additional file 1).
Our data add an important piece of information re-
garding miRNome fluctuation due to ADAR2 in glio-
blastomas, indicating ADAR2 as an important player in
gliomas. Indeed, ADAR2-mediated RNA editing is
strongly dysregulated in glioblastoma cell lines (derived
from adult de novo glioblastoma [42]), in pediatric
[18,21,43] as well as adult gliomas [19,20]. However,
adult and pediatric gliomas are very different tumors at
both the genomic and epigenomic level. For example,
differences in cell methylomes were observed between
pediatric and adult gliomas [44]. In this respect, muta-
tions in the isocitrate dehydrogenase (IDH) 1 and 2
genes, which are able to alter the methylome [45], were
observed in adult and secondary glioblastomas [46], but
not in pediatric or de novo glioblastomas [45]. In order
to see if specific ADAR2 genetic alterations occurred in
gliomas, we analyzed the ADAR2 gene (21q22.3), inter-
rogating different available datasets [47-49]. We did not
identify any somatic aberrations in ADAR2; therefore, it
is more likely that epigenetic/post-transcription events
are responsible for its inactivation during gliomagenesis.
Future studies, including a comprehensive analysis of
molecular pathways and of ADAR2-mediated RNA edit-
ing profiles, should further provide important informa-
tion about changes in genetic, epigenetic and post-
transcriptional mechanisms among different groups of
gliomas.
Conclusions
We propose ADAR2 as a ‘radar’ enzyme that maintains
a degree of editing in the miRNA population and balances
miRNA expression, maintaining them at physiological,
that is, safe, levels. Whenever ADAR2 is impaired (that is,
in glioblastoma), miRNA homeostasis is altered and this
may contribute to cancer progression (Figure 10). In sum-
mary, our findings identify ADAR2 as a promising target
for an innovative anti-tumoral strategy, since ADAR2
alone can simultaneously modulate more than one
miRNA and cellular pathway altered in cancer cells.
Future studies on dissecting the causes of ADAR2 de-
regulation will be aimed at the identification of com-
pounds that can adjust ADAR2 expression/activity in
glioblastoma and provide a potential anti-cancer therapy.
Materials and methods
Cell lines
Well-characterized permanent human glioblastoma cell
lines U118 MG (HTB-15™) and A172 (CRL-1620™), derived
from adult patients with malignant de novo glioblastoma
[42], were obtained from American Type Culture Collec-
tion (ATCC). Human embryonic kidney 293 T (HEK293T,
CRL-1573™) and human cervical cancer (HeLa, CCL2™)
cells were obtained from ATCC. All the cell lines were
Figure 9 Cartoon summarizing the role played by ADAR2
over p27Kip1.
Figure 10 Cartoon summarizing the role played by ADAR2 in cancer versus normal cells/tissues. ADAR2 editing activity rebalances miRNA
expression and recovers the edited miRNA population. Dark blue dots represent editing events present in normal brain but absent
in glioblastoma.
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routinely maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (Gibco-Life Technologies, Carlsbad, CA, USA),
100 U/ml penicillin and 100 μg/ml streptomycin, at
37°C in 5% CO2. U118 and A172 cell lines stably over-
expressing the active EGFP-ADAR2 or the inactive
EGFP-ADAR2 E/A enzyme were generated as previ-
ously reported [18,21]. The U118 ADAR2 cell line sta-
bly silenced for ADAR2 (siADAR2) and the scramble
were generated as previously described [21]. All the
stable cell lines used in this study were polyclonal to
avoid problems due to positional insertion effects.
Human and mouse brain tissues/RNAs
Brain tissues from homozygous Adar2 knockout and
control mice were kindly supplied by Dr Michael
Jantsch. Mouse tissues were obtained in accordance with
the local (Austria) research ethics regulations. We used
total RNA of human adult brains from a pool of 23 indi-
viduals (AM6050, Ambion-Life Technologies, Carlsbad,
CA, USA) and from an 18-year-old single donor (636530,
Clontech, Mountain View, CA, USA). Furthermore, we
used normal human brain tissue obtained from a pediatric
donor (undergoing focal brain resection for head injury
sequelae) and a de novo glioblastoma (grade IV astrocy-
toma) tissue. The study was revised and approved by the
local institutional review board (study number 571/2012)
of Bambino Gesù Children’s Hospital of Rome. Informed
consent from patients was obtained for the use of bio-
logical samples for research purposes.
RNA isolation
The small (up to 200 nucleotide) and total RNA frac-
tions were isolated using miRVana™ miRNA Isolation Kit
(Ambion-Life Technologies) and TRIzol reagent (Invi-
trogen-Life Technologies, Carlsbad, CA, USA), respect-
ively. Both procedures were performed according to the
manufacturer’s recommendations. RNA concentration
and purity (A260/A280nm ratio) were evaluated using
NanoDrop ND-2000 (Thermo Scientific, Walthman,
MA, USA). RNA quality was assessed by gel electrophor-
esis or by an Agilent 2100 Bioanalyzer microfluidics-based
platform (Agilent Technologies, Santa Clara, CA, USA)
with two chips: Agilent RNA 6000 Nano Kit for total
RNA and Agilent Small RNA kit for low molecular weight
RNA. RNA samples were DNase treated (Ambion-Life
Technologies).
miRNA microarray
Microarray experiments were performed using a miR-
CURY™ LNA microRNA Array Power Labeling Kit
(Exiqon, Vedbaek, Denmark). Total RNA from U118,
U118 ADAR2 and U118 ADAR2 E/A were labeled with
specific fluorescent dyes (Hy3 and Hy5), following
Exiqon’s protocol. Fluorochrome-labeled RNA samples
were then combined, denatured and hybridized on home-
made slides, containing LNA-modified microRNA capture
probes targeting all human miRNAs listed in miRBASE
v.8.1 [50]. The hybridization was performed according to
the miRCURY™ LNA array manual using hybridization
chambers (Agilent Technologies), for 16 h at 56°C. A
ScanArray Lite Microarray Scanner (Packard Bioscience
Company, Arvada, CO, USA was used to acquire images
and the software GenePix Pro 6.0 was used to quantify
hybridization signals. Microarray images were processed
and analyzed using Genepix Pro 6.0, Excel and TIGR
Multiexperiment Viewer v.4.0. Data were normalized
using different endogenous controls present in the LNA-
modified spotted library. The Hy3/Hy5 ratios of ADAR2
versus ADAR2 E/A were log2-transformed and data from
three independent experiments were averaged. To identify
the miRNAs with a statistically significant difference of
expression, we used the Benjamini-Hochberg multiple-
testing correction for the t-test results. We adopted a FDR
cutoff of 0.2 (FDR ≤ 0.2) that ensures a global statistical
accuracy of 80%. We selected only miRNAs with a log2
(ratio) above +0.5 or below -0.5.
miRNA deep-sequencing: editing and expression profiling
miRNA capture and library construction were conducted
using Illumina’s TruSeq Small RNA Sample Prep Kit ac-
cording to the manufacturer’s protocol (Illumina, San
Diego, CA, USA). The mature miRNA libraries were
sequenced with barcodes on one lane of an Illumina
HiSeq2000 instrument following the manufacturer’s
protocol. The total number of reads was 16.8 million,
35.6 million, 21.6 million and 36.5 million for the U118
untreated, ADAR2, ADAR2 E/A and siADAR2 cell lines,
respectively, and 10 million, 40 million and 124 million
for the Ambion pool of adult brains, frontal lobe sample
and glioblastoma sample, respectively. All reads were fil-
tered such that the quality of each read will not be below
a given threshold value (chosen to be 20) in more than
three positions. In addition, sequences identified as 5′ or
3′ adaptors were removed. After adaptor trimming,
reads longer (>28 bases) or shorter (<15 bases) than the
typical length of a mature miRNA were also removed.
Editing events were identified as previously described
[23]. Briefly, considering that the 3′ end of mature reads
undergoes extensive modifications [51], the last two
bases of the read were trimmed [52]. The filtered and
trimmed reads were aligned using Bowtie [53] against
the human genome (UCSC hg19/GRCh37) allowing up
to one mismatch with quality score (phred score) of 30
and above. The total number of reads aligned to known
miRNAs (miRBase, release 17) [54] was 4.3 million, 6.7
million, 6.6 million and 6.3 million for U118 untreated,
ADAR2, ADAR2 E/A and siADAR2 cells, respectively,
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and 1.4 million, 3.2 million and 1.1 million for Ambion’s
pool of adult brains, frontal lobe sample and glioblast-
oma sample, respectively. All the locations in each ma-
ture or miRNA* were screened for mismatches that
were overrepresented considering the expected sequen-
cing error rate of 0.1% (as only mismatches with phred
score of 30 were allowed). This was done by applying
the binomial cumulative distribution on the counts of
each sequenced nucleotide. All the miRNA expression
profiles were normalized and statistically significant differ-
ences between the profiles were identified as described
previously [25]. Briefly, the expression profiles were nor-
malized using a variation of the trimmed mean of M-
values normalization method [25,55]. Then, we looked for
expression differences that cannot be explained by the ex-
pected Poisson noise with P-value <0.05 and Bonferroni
correction for multiple testing. Fold-changes between
counts of sample A and B were calculated using the for-
mula log2[(A + 1)/(B + 1)], in order to avoid problems as-
sociated with zero values.
Quantitative real-time-PCR
qRT-PCRs were performed to validate the expression of
specific mature miRNAs, using pre-designed stem-loop
primers (TaqMan MicroRNA Assay, Applied Biosystems-
Life Technologies). cDNA was synthesized from 10 ng of
total RNA using TaqMan MiR Reverse Transcriptase Kit
(Applied Biosystems-Life Technologies) according to the
manufacturer’s instructions.
For pri-miRNA and mRNA, 1 μg of total RNA (pre-
treated with DNase I) was used to generate cDNA by
the ImProm-II Reverse Transcription System (Promega,
Madison, WI, USA) using random hexamer primers ac-
cording to the manufacturer’s instructions.
Custom stem-loop primers were designed for the detec-
tion of pre-miRNAs (Applied Biosystems-Life Technolo-
gies). A pre-amplification step was introduced for the
detection of pre-miRNAs to increase the sensitivity of the
following real-time PCR analysis [56]. Briefly, the pre-
amplification reaction was carried out using Taqman Pre-
Amp Master Mix (Applied Biosystems-Life Technologies)
and the following cycling conditions: 95°C for 10 minutes,
14 cycles of 95°C for 15 s and 60°C for 4 minutes, followed
by a hold at 4°C. qRT-PCRs were conducted on an ABI
PRISM 7700 Sequence Detection System (Applied
Biosystems-Life Technologies) using TaqMan Univer-
sal PCR MasterMix. The small endogenous nuclear
RNA U6 (RNU6B) and GAPDH were used as controls
for normalization of mature miRNAs/pre-miRNAs and
mRNAs/pri-miRNAs, respectively. The relative amount of
each substrate was calculated by the 2-ΔΔCT method [57].
Expression levels were represented as a relative-fold in-
crease compared with the control sample arbitrarily set
to 1. All qRT-PCRs were performed in duplicates and
repeated at least two times from independent RT-PCRs.
All the primers were supplied by Applied Biosystems:
miR-221, ID 000524; miR-221*, ID 002096; miR-222, ID
002276; miR-222*, ID 000525; miR-21, ID 000397;
miR-223, ID 002295; RNU6B, ID 001093; pri-miR-221,
ID Hs03303007_pri and Mm03307181_pri; pri-miR-222,
ID Hs03303011_pri and Mm03307187_pri; pri-miR-21,
ID Hs03302625_pri and Mm03306822_pri; ADAR2, ID
Hs00953730_m1; GAPDH, ID Hs99999905_m1; Actb,
ID Mm00607939_s1.
RNA editing analysis by Sanger sequencing
For the editing analysis, RNA samples were pretreated
with DNase I and cDNAs were generated with Superscript
II Reverse Transcriptase (Invitrogen-Life Technologies)
using random hexamer primers or transcript-specific oli-
gonucleotides, according to the manufacturer’s instruc-
tions. The cDNAs were amplified by PCR reactions using
Expand high fidelity Plus PCR System (Roche, Basel,
Switzerland) and specific primers. The specific PCR
products were gel purified (Qiaquick, Qiagen, Venlo,
Limburgo, Netherlands), directly sequenced or cloned
into pGEM T-easy vector (Promega) and transformed
into Escherichia coli.
Direct sequencing (ABI 3500 Genetic Analyzer, Applied
Biosystems-Life Technologies) was performed on cDNA
pools and editing levels were calculated as previously de-
scribed [18,58]. Briefly, editing was quantified dividing the
area under the curve (AUC) of the G peak by the sum of
the AUC of A and G peaks of the analyzed site. For single
clone analysis, approximately 40 to 100 individual cDNA
clones were sequenced for each sample using T7 or Sp6
primers and A-to-G changes in the individual clones were
analyzed. All primer sequences used for these studies are
available on request.
RNA editing analysis by MiSeq technology
The specific PCR products of pri-miR-221, pri-miR-222
and pri-miR-21 from different samples were gel purified,
quantified and used in equimolar amounts. Dual-indexed
paired-end libraries for subsequent cluster generation
and DNA sequencing of amplicon pools were prepared
using Illumina Nextera®XT DNA Sample Preparation
Kit (Illumina), as recommended in the manufacturer’s
instructions. MiSeq sequencing of the sample libraries
was performed using the MiSeq Reagent Nano Kit v2
(300 cycles) and analysis of the reads produced was per-
formed by IGV (Integrative Genomics Viewer) software [59].
Northern blot
For northern blot analysis of miRNAs, 20 μg of total
RNA was separated on 10% denaturing polyacrylamide
gels, electroblotted onto Immobilon Nylon+ membrane
(Millipore Corp., Billerica, MA, USA) and UV-crosslinked.
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The specific probes were end-labeled using T4 poly-
nucleotide kinase and [γ-32P] ATP. Oligonucleotide
probes, corresponding to the antisense miRNA se-
quences used, were: miR-221 probe, 5′-gaaacccagcaga-
caatgtagc-3′; miR-222 probe, 5′-gagacccagtagccagat-3′;
miR-21 probe, 5′-tcaacatgagtctgataagcta-3′; and U6 probe,
5′-cacgaatttgcgtgtcatccttgcgcaggggcc-3′. Hybridization
was done at 37°C in 0.1% SDS, 5X Denhardt’s and 6X
SSPE overnight and membranes were washed at 42°C
with 6X SSPE. Membranes were stripped by boiling in
0.1% SDS and rehybridized. U6 RNA was used as control.
Immunoblotting
Total protein extracts were isolated with RIPA lysis buffer
in the presence of a protease inhibitor mixture and
phosphatase inhibitor cocktail (Sigma-Aldrich, St. Luis,
MO, USA). Protein extracts were quantified with a BCA
Protein Assay Kit (Pierce Biotechnology, Rockford, IL,
USA). Equal amounts of total cellular lysates (30 μg)
were separated by SDS-PAGE, transferred on nitrocellu-
lose membrane, analyzed by immunoblotting with the
appropriate antibodies and then revealed by ECL (en-
hanced chemiluminescence) (GE Healthcare, Bucking-
hamshire, UK). The antibodies used in this study were:
anti-p27 (1:500; Cell Signaling, Danvers, MA, USA),
anti-PDCD4 (1:1,000; Origene Technologies, Rockville,
MD, USA), anti-ADAR2 (1:200; Sigma), anti-β-actin
(1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and anti-GAPDH (1:5,000; Cell Signaling). The
protein-specific signals were quantified by densitomet-
ric analysis using ImageJ v1.47 software.
Plasmid constructs and cell transfection
The pri-miR-222/221 cluster sequence was amplified by
PCR from genomic human DNA using the following
primers: miR-222/221 sense, 5′-cgcagatcttttcttccacag
agcccctcc-3′; miR-222/221 antisense, 5′-gctcgaggcgg
tcctttctctgcactct-3′. The correct sequences of amplified
products were verified by sequencing and cloned into
the BamHI-XhoI sites of pCDNA(+)3.1 vector. The
pCMV-miR-21 vector was obtained from Origene Tech-
nologies. The plasmid containing the pri-miR-223 se-
quence was kindly provided by Dr Alessandro Fatica
(Sapienza University, Rome). EGFP-ADAR2 and EGFP-
ADAR2 E/A constructs were generated as previously
described [18].
HEK293T cells seeded into a six-well plate were tran-
siently co-transfected at 80% confluence using Lipofec-
tamine 2000 (Invitrogen-Life Technologies) with either
2 μg of EGFP-ADAR2 or EGFP-ADAR2 E/A in the
presence of 1.5 μg of pri-miR-222/221 or pri-miR-21
plasmid. After 48 h, the cells were collected and
analyzed.
Site-directed mutagenesis to generate edited
pri-miR-221, -222 and -21
A-to-G single point mutations in the pri-miR-221, -222,
-21 sequences were introduced using a site-directed mu-
tagenesis kit (Agilent Technologies) following the manu-
facturer’s instructions. The oligonucleotides used for the
mutagenesis are available on request.
miRNA mimic transfection
One day before transfection, U118 and A172 cells (8 ×
105/well) were plated into a six-well plate. miRIDIAN
miRNA mimics (small, chemically modified dsRNAs that
mimic endogenous miRNAs; Dharmacon-GE Health-
care, Lafayette, CO, USA) miR-221, miR-222 or miR-21
(100 nM or 200 mM) were transfected into cells using
Oligofectamine (Invitrogen-Life Technologies), accord-
ing to the manufacturer’s instructions, and then tested
for in vitro proliferation and motility.
Proliferation assay
The day after transfection, cell viability (trypan blue dye
exclusion) was determined daily, from day 1 to day 3.
Monolayer wounding assay
For evaluation of in vitro motility, a monolayer wound-
ing (scratch) assay was performed. Cells were allowed to
form a monolayer on a culture dish surface and, when
approaching 100% cell confluence, a wound was made
by scratching the monolayer with a pipette tip. After the
scratching, the cells were incubated in a 5% CO2 incuba-
tor at 37°C for further 24 h. Photographs of the wound
were taken at various time points after wounding. Two
independent series of experiments were performed.
Data availability
The miR-seq data were deposited to the Sequence Read
Archive (SRA), under the following accession codes:
SRX735409 (U118 ADAR2), SRX735410 (U118 ADAR2
E/A), SRX764455 (U118 siADAR2), SRX039177 (brain
Ambion), SRX747635 (glioblastoma). The miR-array
data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus (GEO) and are
accessible through GEO Series accession number GSE63694.
The manuscript’s experimental methods comply with
the Helsinki declaration.
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expression levels [log2(ratio)] as a result of ADAR2 and ADAR2 E/A
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Additional file 3: Table S2. Mature miRNAs with statistically significant
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ADAR2 versus U118 ADAR2 E/A and which inverted their expression
trend in the U118 siADAR2 cell line.
Additional file 4: Table S3. Mature miRNAs with significant changes in
expression levels (log2(ratio) of at least ±0.5) between normal human
brain versus glioblastoma.
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